COMP <GO>
LXRX vs JNJ // DIVIDEND YIELD & FCF PAYOUT SAFETY
Lexicon Pharmaceuticals Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: LXRX 2
— JNJ 7
■ METRIC PARITY
LAST: $1.48 (-0.34%) • MKT CAP: $658.5M
dividend-safety
0.00%
LAST: $275.20 (+1.54%) • MKT CAP: $662.49B
dividend-safety
0.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LXRX VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LXRX | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 96.00% | 67.90% | +28.10 | LXRX | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -31.50% | 25.50% | -57.00 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -10.30% | 2.97% | -13.27 | JNJ | /fcf-yield <GO> |
| Operating Margin | -60.00% | 34.70% | -94.70 | JNJ | /operating-margins <GO> |
| Net Profit Margin | -60.00% | 28.50% | -88.50 | JNJ | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | 6.00% | +174.00 | LXRX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 5.59 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 8/9 | -3.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 29.1 | 62.1 | -33.05 | JNJ | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.08 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 23.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $658.5M | $662.49B | -$661.83B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LXRX REV | JNJ REV | LXRX GROSS % | JNJ GROSS % | LXRX FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $49.8M | $94.19B | 98.0% | 67.9% | -$67.9M | $19.70B |
| FY 2024 | $6.0M | $88.82B | 89.7% | 69.1% | -$179.8M | $19.84B |
| FY 2023 | $1.1M | $85.16B | — | — | -$161.9M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LXRX // BETA —
JNJ // BETA 1.08